Drug Profile


Alternative Names: Antexan; CV 4151

Latest Information Update: 09 Nov 2000

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Takeda
  • Class Anti-ischaemics; Antiplatelets; Ischaemic heart disorder therapies; Monounsaturated fatty acids; Pyridines; Small molecules
  • Mechanism of Action Thromboxane A2 receptor antagonists; Thromboxane synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias; Thrombosis; Transient ischaemic attacks

Most Recent Events

  • 09 Nov 2000 Discontinued-preregistration for Transient ischaemic attacks in Japan (Unknown route)
  • 08 Nov 2000 Discontinued-Preclinical for Arrhythmias in Japan (Unknown route)
  • 08 Nov 2000 Investigation in Thrombosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top